Stocks › CAR-T Therapy › AMGN

Amgen AMGN

US equityMarket cap rank #67CAR-T Therapy

$404.52

−$1.57 (-0.39%)

Market open · Sep 24, 1:10 pm ET

After hours $405.00 -0.27%

Open$406.09

Prev close$406.09

Day range$403.88 – $409.99

Volume626.8K

Market cap$218.69B

P/E (TTM)25.1

Dividend yield2.42%

Scotiabank Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $450 Market news · 9 Sep 2026
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $317 to $452 Market news · 9 Sep 2026
Citi Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $405 Market news · 9 Sep 2026
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating Market news · 8 Sep 2026
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $457 Market news · 8 Sep 2026
Setback for the second time in a week! Novartis (NVS.US) sees its blockbuster heart disease drug fail in Phase III trials, causing a sharp drop in share price; Amgen (AMGN.US) suffers collateral damage. Zhitong Finance · 7 Sep 2026
Amgen | 3: Initial statement of beneficial ownership of securities- Dittrich Thomas J.W. SEC · 5 Sep 2026
Amgen | 4: Statement of changes in beneficial ownership of securities-Officer Grygiel Nancy A. SEC · 8 Aug 2026
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating Market news · 28 Aug 2026
Scotiabank Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $450 Market news · 28 Aug 2026
William Blair Maintains Amgen(AMGN.US) With Buy Rating Market news · 27 Aug 2026
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $452 Market news · 27 Aug 2026
Amgen Advances Tarlatamab Shot Vs. Infusion in Phase 3 Lung Cancer Study TipRanks · 22 Aug 2026
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $457 Market news · 20 Aug 2026
Amgen | 4: Statement of changes in beneficial ownership of securities-Director Klotman Mary E. SEC · 22 May 2026